Synthesis, antitumor activity, and electrochemical behavior of some piperazinyl amidrazones

Raid Jamil Abdel-Jalil, Ehab Q. El Momani, Muawiah Hamad, Wolfgang Voelter, Mohammad S. Mubarak, Bianna H. Smith, Dennis G. Peters

Research output: Contribution to journalArticle

36 Citations (Scopus)

Abstract

New piperazinyl amidrazones have been synthesized by direct interaction of the corresponding aryl hydrazones with the appropriate piperazine. On the basis of preliminary screening data for these new compounds, the antitumor activity of 1-(4-methylpiperazin-1-yl)-1,2-propan-dione 1-[2-(4-chlorophenyl)hydrazone] and 1-(4-ethylpipera-zin- 1-yl)-1,2-propandione 1-[2-(4-chlorophenyl)hydrazone] was evaluated. Mean 50% growth inhibition (GI50, 50% cell killing (LC50, and total growth inhibition (TGI) for both compounds were calculated on the basis of data obtained from 55 test cell lines. Mean GI 50 is significantly lower for the methylpiperazine derivative (4.81 μM) compared with that of the ethylpiperazine derivative (4.92 μM) (p > 0.01); however, mean TGI is not measurably different (p > 0.1) for both compounds (4.52 and 4.52 μM, respectively). Both compounds exhibit substantial antitumor activity against a number of cell lines at 4 μM concentration. It was found that the methylpiperazine derivative is more potent against leukemia cell lines (mean GI50 = 4.73 μM and mean TGI = 4.36 μM), whereas the ethylpiperazine derivative is more potent against CNS cell lines (GI50 = 4.68 μM and mean TGI = 4.37 μM). Cancers of the breast are least susceptible to methylpiperazine derivative activity compared with all other cell lines (mean GI50 = 4.91 μM). Melanomas and renal cancers are least susceptible to the ethylpiperazine derivative activity as compared with other cancer types (mean GI50 = 5.06 μM). Cyclic voltammetry has been employed to probe the electrochemical oxidation and reduction of the piperazinyl amidrazones at glassy carbon electrodes in dimethylformamide containing tetramethylammonium tetrafluoroborate.

Original languageEnglish
Pages (from-to)251-258
Number of pages8
JournalMonatshefte fur Chemie
Volume141
Issue number2
DOIs
Publication statusPublished - Feb 2010

Fingerprint

Cells
Derivatives
Hydrazones
Dimethylformamide
Electrochemical oxidation
Glassy carbon
Cyclic voltammetry
Screening
Electrodes

Keywords

  • Cancer drugs CNS cancers
  • Cyclic voltammetry
  • Piperazinyl amidrazones

ASJC Scopus subject areas

  • Chemistry(all)

Cite this

Abdel-Jalil, R. J., El Momani, E. Q., Hamad, M., Voelter, W., Mubarak, M. S., Smith, B. H., & Peters, D. G. (2010). Synthesis, antitumor activity, and electrochemical behavior of some piperazinyl amidrazones. Monatshefte fur Chemie, 141(2), 251-258. https://doi.org/10.1007/s00706-009-0241-4

Synthesis, antitumor activity, and electrochemical behavior of some piperazinyl amidrazones. / Abdel-Jalil, Raid Jamil; El Momani, Ehab Q.; Hamad, Muawiah; Voelter, Wolfgang; Mubarak, Mohammad S.; Smith, Bianna H.; Peters, Dennis G.

In: Monatshefte fur Chemie, Vol. 141, No. 2, 02.2010, p. 251-258.

Research output: Contribution to journalArticle

Abdel-Jalil, RJ, El Momani, EQ, Hamad, M, Voelter, W, Mubarak, MS, Smith, BH & Peters, DG 2010, 'Synthesis, antitumor activity, and electrochemical behavior of some piperazinyl amidrazones', Monatshefte fur Chemie, vol. 141, no. 2, pp. 251-258. https://doi.org/10.1007/s00706-009-0241-4
Abdel-Jalil, Raid Jamil ; El Momani, Ehab Q. ; Hamad, Muawiah ; Voelter, Wolfgang ; Mubarak, Mohammad S. ; Smith, Bianna H. ; Peters, Dennis G. / Synthesis, antitumor activity, and electrochemical behavior of some piperazinyl amidrazones. In: Monatshefte fur Chemie. 2010 ; Vol. 141, No. 2. pp. 251-258.
@article{d81e027f702740b29d29a46fc36cbc88,
title = "Synthesis, antitumor activity, and electrochemical behavior of some piperazinyl amidrazones",
abstract = "New piperazinyl amidrazones have been synthesized by direct interaction of the corresponding aryl hydrazones with the appropriate piperazine. On the basis of preliminary screening data for these new compounds, the antitumor activity of 1-(4-methylpiperazin-1-yl)-1,2-propan-dione 1-[2-(4-chlorophenyl)hydrazone] and 1-(4-ethylpipera-zin- 1-yl)-1,2-propandione 1-[2-(4-chlorophenyl)hydrazone] was evaluated. Mean 50{\%} growth inhibition (GI50, 50{\%} cell killing (LC50, and total growth inhibition (TGI) for both compounds were calculated on the basis of data obtained from 55 test cell lines. Mean GI 50 is significantly lower for the methylpiperazine derivative (4.81 μM) compared with that of the ethylpiperazine derivative (4.92 μM) (p > 0.01); however, mean TGI is not measurably different (p > 0.1) for both compounds (4.52 and 4.52 μM, respectively). Both compounds exhibit substantial antitumor activity against a number of cell lines at 4 μM concentration. It was found that the methylpiperazine derivative is more potent against leukemia cell lines (mean GI50 = 4.73 μM and mean TGI = 4.36 μM), whereas the ethylpiperazine derivative is more potent against CNS cell lines (GI50 = 4.68 μM and mean TGI = 4.37 μM). Cancers of the breast are least susceptible to methylpiperazine derivative activity compared with all other cell lines (mean GI50 = 4.91 μM). Melanomas and renal cancers are least susceptible to the ethylpiperazine derivative activity as compared with other cancer types (mean GI50 = 5.06 μM). Cyclic voltammetry has been employed to probe the electrochemical oxidation and reduction of the piperazinyl amidrazones at glassy carbon electrodes in dimethylformamide containing tetramethylammonium tetrafluoroborate.",
keywords = "Cancer drugs CNS cancers, Cyclic voltammetry, Piperazinyl amidrazones",
author = "Abdel-Jalil, {Raid Jamil} and {El Momani}, {Ehab Q.} and Muawiah Hamad and Wolfgang Voelter and Mubarak, {Mohammad S.} and Smith, {Bianna H.} and Peters, {Dennis G.}",
year = "2010",
month = "2",
doi = "10.1007/s00706-009-0241-4",
language = "English",
volume = "141",
pages = "251--258",
journal = "Monatshefte fur Chemie",
issn = "0026-9247",
publisher = "Springer Wien",
number = "2",

}

TY - JOUR

T1 - Synthesis, antitumor activity, and electrochemical behavior of some piperazinyl amidrazones

AU - Abdel-Jalil, Raid Jamil

AU - El Momani, Ehab Q.

AU - Hamad, Muawiah

AU - Voelter, Wolfgang

AU - Mubarak, Mohammad S.

AU - Smith, Bianna H.

AU - Peters, Dennis G.

PY - 2010/2

Y1 - 2010/2

N2 - New piperazinyl amidrazones have been synthesized by direct interaction of the corresponding aryl hydrazones with the appropriate piperazine. On the basis of preliminary screening data for these new compounds, the antitumor activity of 1-(4-methylpiperazin-1-yl)-1,2-propan-dione 1-[2-(4-chlorophenyl)hydrazone] and 1-(4-ethylpipera-zin- 1-yl)-1,2-propandione 1-[2-(4-chlorophenyl)hydrazone] was evaluated. Mean 50% growth inhibition (GI50, 50% cell killing (LC50, and total growth inhibition (TGI) for both compounds were calculated on the basis of data obtained from 55 test cell lines. Mean GI 50 is significantly lower for the methylpiperazine derivative (4.81 μM) compared with that of the ethylpiperazine derivative (4.92 μM) (p > 0.01); however, mean TGI is not measurably different (p > 0.1) for both compounds (4.52 and 4.52 μM, respectively). Both compounds exhibit substantial antitumor activity against a number of cell lines at 4 μM concentration. It was found that the methylpiperazine derivative is more potent against leukemia cell lines (mean GI50 = 4.73 μM and mean TGI = 4.36 μM), whereas the ethylpiperazine derivative is more potent against CNS cell lines (GI50 = 4.68 μM and mean TGI = 4.37 μM). Cancers of the breast are least susceptible to methylpiperazine derivative activity compared with all other cell lines (mean GI50 = 4.91 μM). Melanomas and renal cancers are least susceptible to the ethylpiperazine derivative activity as compared with other cancer types (mean GI50 = 5.06 μM). Cyclic voltammetry has been employed to probe the electrochemical oxidation and reduction of the piperazinyl amidrazones at glassy carbon electrodes in dimethylformamide containing tetramethylammonium tetrafluoroborate.

AB - New piperazinyl amidrazones have been synthesized by direct interaction of the corresponding aryl hydrazones with the appropriate piperazine. On the basis of preliminary screening data for these new compounds, the antitumor activity of 1-(4-methylpiperazin-1-yl)-1,2-propan-dione 1-[2-(4-chlorophenyl)hydrazone] and 1-(4-ethylpipera-zin- 1-yl)-1,2-propandione 1-[2-(4-chlorophenyl)hydrazone] was evaluated. Mean 50% growth inhibition (GI50, 50% cell killing (LC50, and total growth inhibition (TGI) for both compounds were calculated on the basis of data obtained from 55 test cell lines. Mean GI 50 is significantly lower for the methylpiperazine derivative (4.81 μM) compared with that of the ethylpiperazine derivative (4.92 μM) (p > 0.01); however, mean TGI is not measurably different (p > 0.1) for both compounds (4.52 and 4.52 μM, respectively). Both compounds exhibit substantial antitumor activity against a number of cell lines at 4 μM concentration. It was found that the methylpiperazine derivative is more potent against leukemia cell lines (mean GI50 = 4.73 μM and mean TGI = 4.36 μM), whereas the ethylpiperazine derivative is more potent against CNS cell lines (GI50 = 4.68 μM and mean TGI = 4.37 μM). Cancers of the breast are least susceptible to methylpiperazine derivative activity compared with all other cell lines (mean GI50 = 4.91 μM). Melanomas and renal cancers are least susceptible to the ethylpiperazine derivative activity as compared with other cancer types (mean GI50 = 5.06 μM). Cyclic voltammetry has been employed to probe the electrochemical oxidation and reduction of the piperazinyl amidrazones at glassy carbon electrodes in dimethylformamide containing tetramethylammonium tetrafluoroborate.

KW - Cancer drugs CNS cancers

KW - Cyclic voltammetry

KW - Piperazinyl amidrazones

UR - http://www.scopus.com/inward/record.url?scp=77952583255&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77952583255&partnerID=8YFLogxK

U2 - 10.1007/s00706-009-0241-4

DO - 10.1007/s00706-009-0241-4

M3 - Article

AN - SCOPUS:77952583255

VL - 141

SP - 251

EP - 258

JO - Monatshefte fur Chemie

JF - Monatshefte fur Chemie

SN - 0026-9247

IS - 2

ER -